German pharmaceutical giant Boehringer Ingelheim said China remains a market of continued interest and would keep up the ...

Sanofi is to take on Boehringer Ingelheim's consumer health division ... division – except its business in China – being exchanged at a price of €6.7 billion. The deal is one of the biggest ...

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address ...

Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.

Last year, Boehringer Ingelheim supported livestock producers and governments ... primarily due to transitioning to renewable solutions at various sites, including Japan and China. A new biomass power ...

The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune ...

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient ...